By administering two different TMs (one RevTM-CD123 and the other RevTM-CD33), the same RevCAR-T cell could be targeted by the TM to a CD123+ or CD33+ tumor cell and, by activating the effector mechanism, lead to its elimination. The gene discussed is IL3RA; the disease is neoplasm.